Vancomycin Hydrochloride is owned by Xellia Pharms Aps.
Vancomycin Hydrochloride contains Vancomycin Hydrochloride.
Vancomycin Hydrochloride has a total of 5 drug patents out of which 0 drug patents have expired.
Vancomycin Hydrochloride was authorised for market use on 15 February, 2019.
Vancomycin Hydrochloride is available in solution;intravenous dosage forms.
Vancomycin Hydrochloride can be used as method of treating bacterial infections.
The generics of Vancomycin Hydrochloride are possible to be released after 06 November, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11628200 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 February, 2019
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS
9
United States
4
European Union
2
Croatia
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Japan
2
Slovenia
2
RS
2
Hungary
1
Colombia
1
Australia
1
EA
1
Israel
1
Korea, Republic of
1
Canada
1
Tunisia
1
Saudi Arabia
1
Costa Rica
1
Chile
1
Singapore
1
Philippines
1
Mexico
1
Brazil
1
South Africa
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic